NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 230,100 shares, an increase of 42.7% from the January 31st total of 161,300 shares. Currently, 1.6% of the company’s shares are short sold. Based on an average daily volume of 273,600 shares, the days-to-cover ratio is currently 0.8 days.

NeuroSense Therapeutics Stock Performance

Shares of NRSN stock traded down $0.06 during mid-day trading on Monday, hitting $1.05. The company’s stock had a trading volume of 198,043 shares, compared to its average volume of 143,239. The company has a market cap of $14.35 million, a PE ratio of -1.64 and a beta of 1.27. The company’s fifty day simple moving average is $1.13 and its 200-day simple moving average is $1.12. NeuroSense Therapeutics has a 52 week low of $0.51 and a 52 week high of $2.29.

NeuroSense Therapeutics (NASDAQ:NRSN) last issued its earnings results on Wednesday, December 18th. The company reported ($0.11) earnings per share for the quarter.

Institutional Trading of NeuroSense Therapeutics

Several hedge funds have recently modified their holdings of the stock. XTX Topco Ltd grew its holdings in NeuroSense Therapeutics by 40.9% in the third quarter. XTX Topco Ltd now owns 45,996 shares of the company’s stock worth $58,000 after purchasing an additional 13,346 shares during the period. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics during the 4th quarter worth about $78,000. Finally, Citadel Advisors LLC boosted its position in shares of NeuroSense Therapeutics by 640.9% during the 4th quarter. Citadel Advisors LLC now owns 253,997 shares of the company’s stock worth $305,000 after purchasing an additional 219,717 shares in the last quarter. Institutional investors own 1.04% of the company’s stock.

Analyst Ratings Changes

Separately, Maxim Group reissued a “hold” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 16th.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.